Medtec上海国际医疗器械设计与制造技术展览会

2025. 09.24-26
上海世博展览馆1号馆&2号馆

2026. 9.1-9.3

上海新国际博览中心 N1-N4

距离展会

Unique concept for modern wound dressings

Covestro, formerly Bayer MaterialScience, is presenting its innovative Baymedix® polyurethane (PU) technology for modern wound dressings. Foams, adhesives and films manufactured from these materials as well as specialty films from the Platilon® product portfolio enable optimal moisture management in wound dressings, which is essential for improving the quality of patient care.

3-6-2

Modern wound dressings can be produced efficiently and sustainably from just three components if the Baymedix® and Platilon® materials are combined appropriately. The direct application of the adhesive or foam to the film eliminates laminating steps. Wound dressings based on the Covestro PU technology are also well suited for advanced negative pressure wound therapy.

“Our Baymedix® product portfolio enables us to fulfill the desire of many manufacturers to generate added value through innovation and differentiation, and to thus improve their own competitiveness,” says Martin Huettner, Marketing Manager Medical at Covestro. “This is difficult to achieve with the established raw materials on the market.”

The differences are particularly pronounced when it comes to moisture management. Wound dressings made from Covestro materials are air-permeable, exhibit a high absorption capacity and outstanding retention. In addition, the adjustable adhesive strengths of adhesives based on Baymedix® technology make “low trauma removal” – an important issue in wound care – readily achievable. 

About Covestro:
With 2015 sales of EUR 12.1 billion, Covestro is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. Covestro, formerly Bayer MaterialScience, has 30 production sites around the globe and as of the end of the first quarter 2016 employed approximately 15,700 people (full-time equivalents).

This press release is available for download from the Covestro press server at www.covestro.com. Photos are available there for download as well. Please mind the source of the pictures.

Find more information at www.covestro.com.
Follow us on Twitter: www.twitter.com/CovestroGroup

From:Covestro

Medtec上海展|从射频到冷冻,再到脉冲电场:房颤消融技术的第三次跃迁

Medtec上海展留意到过去几年,在全球电生理领域的学术会议上,一个技术名词被频繁提及——PFA(Pulse Field Ablation,脉冲电场消融)。

从欧美大型电生理中心,到亚洲越来越多开展房颤消融的医院,这项技术正在迅速进入临床视野。越来越多专家认为,PFA的出现不仅仅是一次技术升级,更可能意味着房颤消融领域的一次重要转折。

查看更多 »

上海医疗器械博览会|“介入无植入”药物球囊DCB全面逆袭:新证据、新指南、新战场

上海医疗器械博览会关注到系统回顾冠状动脉药物涂层球囊(DCB)在冠心病介入治疗中的发展历程、作用机制、核心适用范围与扩展应用。DCB通过“无植入”策略,避免永久金属支架带来的血栓与再狭窄风险,已在支架内再狭窄(ISR)治疗中确立有效性,并在小血管病变、分叉病变、弥漫长病变、急性冠脉综合征(ACS)、糖尿病与高出血风险人群中展现出广阔潜力。多项随机研究与真实世界数据表明,DCB在特定适应症下可与药物支架(DES)疗效相当甚至优于DES。DCB治疗效果高度依赖病变准备质量,强调使用影像指导、非顺应球囊、切割球囊或旋磨等策略。尽管当前仍需更多高质量前瞻性研究来验证其在非ISR病变中的长期安全性与有效性,但DCB正逐步成为冠脉介入治疗中的重要工具。

查看更多 »

Medtec上海展|国内主要瓣膜玩家与行业突破口浅析

Medtec上海展注意到近年,经皮主动脉瓣膜置换(TAVR)/经皮主动脉瓣膜植入(TAVI)相关的器械赛道非常火热。对于临床医生而言,手里的武器库多了是好事,这意味着更多的器械选择。但是,对于TAVR器械厂家(尤其是对于:还处于研发/动物实验/临床试验/拿证前的厂家和/或者产品线相对单一的厂家)而言,可能就意味着压力较大了。本文对国内TAVR市场中国际及国内TAVR主要玩家进行了较详尽的梳理和分析。水平所限,难免谬误/挂一漏万,请各位同道指正。

查看更多 »